CAS: 85908-96-9; N-Boc-2-Piperidone

相似化合物

675-20-7 4783-65-7 931-20-4

上下游产品

CAS号675-20-7 2-氮己环酮 | CAS号24424-99-5 二碳酸二叔丁酯 | CAS号34619-03-9 碳酸二叔丁酯 | CAS号75844-69-8 1-B°C-哌啶 | CAS号69610-41-9 N-B°C-L-脯氨醛 | CAS号69610-40-8 B°C-L-脯氨醇 | CAS号3466-80-6 2-苯基哌啶 | CAS号1462-93-7 2-乙基-3,4,5,6-四氢吡啶 | CAS号215720-35-7 tert-butyl N-[5... | CAS号195964-51-3 1-B°C-2-Methoxy... | CAS号675-20-7 2-氮己环酮 | CAS号27219-07-4 N-(叔丁氧羰基)-5-氨基戊酸 | CAS号98303-20-9 N-B°C-2-哌啶甲酸 | CAS号865245-32-5 N-叔丁氧羰基-3,4-二氢吡... | CAS号206273-87-2 4-苄氨基哌啶-1-甲酸叔丁酯 | CAS号75844-69-8 1-B°C-哌啶

以 乙腈 作为反应溶剂,化学反应 8.0H,反应生成 1-Boc-2-哌啶酮
参考文献:酰胺与碳酸氢二叔丁酯反应的底物酸度和转化时间
标题:酰胺与碳酸氢二叔丁酯反应的底物酸度和转化时间
摘要:酰胺与四碳酸二叔丁酯的4-二甲基氨基吡啶催化的转化时间随底物酸度的变化而变化.的pk一个的在一些酰胺的dmso被确定为与底物的反应性酸度的支持相关性.特别是酸性的底物,例如4-噻唑烷酮,很容易与各种二碳酸二烷基酯反应.酸性较低的底物与boc 2 O反应,但其他二碳酸二烷基酯优先分解.
DOI:10.1016/0040-4039(95)01931-7

专利信息

专利号:US-6818773-B2
优先权日:2001-10-15
标题:Synthesis of 4-[(Z)-4-bromophenyl)(ethoxyimino) methyl]-1'-[(2,4-dimethyl-1-oxido-3-pyridinyl)carbony)]-4'-methyl-1,4-′bipiperidine
发明人：CHEN MINZHANG; D SA BOSCO ANTHONY; LEONG WILLIAM W; GAN TONG; WONG GEORGE S K; TANG SUHAN; NIELSEN CHRISTOPHER MICHAEL
权利人:SCHERING CORP
摘要:In one embodiment, the present invention describes the synthesis of 4-[(Z)-(4-bromophenyl)(ethoxyimino)methyl]-1'-[(2,4-dimethyl-1-oxido-3-pyridinyl)carbonyl]-4'-methyl-1,4'-bipiperidine, and intermediates therefor from easily available starting materials by a simple route.

专利号:US-7947701-B2
优先权日:2003-11-14
标题:Dual molecules containing peroxy derivative, the synthesis and therapeutic applications thereof
发明人：CAZELLES JEROME; COSLEDAN FREDERIC; MEUNIER BERNARD; PELLET ALAIN
权利人:SANOFI AVENTIS
摘要:The invention relates to dual molecule compounds containing a peroxide derivative, to processes for the synthesis of such compounds, to pharmaceutical compositions comprising such compounds, and to methods of treatment and prevention of malaria comprising administering such compounds and such pharmaceutical compositions.

专利号:US-6326372-B1
优先权日:1999-09-30
标 题:Lactam and cyclic urea derivatives useful as alpha 1a adrenoceptor antagonists
发明人：EVANS BEN E; GILBERT KEVIN F
权利人:MERCK & CO INC
摘要:Lactam and cyclic urea derivatives and their pharmaceutically acceptable salts are disclosed. The synthesis of these compounds and their use as alpha 1a adrenergic receptor antagonists is also described. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are typically selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia can be achieved.

专利号:US-7361765-B2
优先权日:2003-10-27
标 题:Process for the preparation of CCR-2 antagonists
发明人：CAI DONGWEI; FLEITZ FRED; GE MIN; HOERRNER SCOTT; JAVADI GARY; JENSEN MARK; LARSEN ROBERT; LI WENJIE; NELSON DORIAN; SZUMIGALA ELIZABETH; YANG LIHU; ZHOU CHANGYOU
权利人:MERCK & CO INC
摘要:The present invention provides an efficient synthesis for the preparation of ((1R,3S)-3-isopropyl-3-{[3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl]carbonyl}cyclopentyl)[(3S,4S)-3-m ethoxytetrahydro-2H-pyran-4-yl]amine and its succinate salt. The present invention additionally provides an efficient syntheses for the preparation of intermediates (3R)-3-methoxytetrahydro-4H-pyran-4-one; (1S,4S)-4-(2,5-dimethyl-1H-pyrrol-1-yl)-1-isopropylcyclopent-2-ene-1-carboxylic acid; and 3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,6-naphthyridine; and for the preparation of the precursor (3S,4S)-N-((1S,4S)-4-isopropyl-4-{[3-(tri-fluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl]carbonyl}cyclopent-2-en-1-yl)-3-methoxytetrahydro-2H-pyran-4-amine. The invention additionally resides in the superior properties of the succinate salt of ((1R,3S)-3-isopropyl-3-1{[3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl]carbonyl}cyclopentyl)[(3S,4S)-3-methoxytetrahydro-2H-pyran-4-yl]amine

专利号:US-2003105131-A1
优先权日:2001-10-15
标题:Synthesis of 4-[(Z)-4-bromophenyl)(ethoxyimino) methyl]-1'-[(2,4-dimethyl-1-oxido-3-pyridinyl)carbonyl]-4'-methyl-1,4-'bipiperidine

专利号:US-6316437-B1
优先权日:1999-09-30
标题:Spirohydantoin compounds and uses thereof
发明人：HOFFMAN JACOB M
权利人:MERCK & CO INC
摘要:Spirohydantoin compounds and their pharmaceutically acceptable salts are disclosed. The synthesis of these compounds and their use as alpha 1a adrenergic receptor antagonists is also described. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are typically selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia can be achieved.